Skip to main content
. 2024 Feb 8;12(4):440–452. doi: 10.1158/2326-6066.CIR-23-0609

Figure 7.

Figure 7. Schematic model representing the impact of tumor burden on nAg-based vaccine effectiveness. In early disease setting with minimal tumor burden, a vaccine targeting a single neoantigen can be effective. On the contrary, in advanced setting such as metastatic disease, the immunosuppressive tumor microenvironment requires multiple neoantigens and concomitant checkpoint blockade treatment for effective tumor control.

Schematic model representing the impact of tumor burden on nAg-based vaccine effectiveness. In early disease setting with minimal tumor burden, a vaccine targeting a single neoantigen can be effective. On the contrary, in advanced setting such as metastatic disease, the immunosuppressive tumor microenvironment requires multiple neoantigens and concomitant checkpoint blockade treatment for effective tumor control.